NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows Patient wi...
EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trial Trial will evaluate LTI-03, a first-in...
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC ...
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’...
SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseases Phase 1b trial to...
The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are bei...
Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences and pharma industry, announces the official openin...
Kindeva, a global CDMO and drug delivery expert, has officially opened its new UK headquarters at Charnwood Campus Science Innovation and Technology Park...
AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, annou...
Cenevo is launching the Labguru Assistant, an AI-enabled extension to the Labguru solution designed to provide scientists with real-time, in-platform suppo...
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combinati...
Quotient Sciences, a leading global drug development and manufacturing accelerator, and UK technology innovation centre, CPI, have signed a memorandum of...
CDT Equity Inc. announces that it has successfully identified a new biological target and novel therapeutic indication for its lead programme, AZD1...
Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces the completion of a major enhancemen...
© 2025 Biopharma Boardroom. All Rights Reserved.
